| 产品名称： | Equid herpesvirus 1 |
|---|---|
| 商品货号： | TS213631 |
| Classification： | Herpesviridae, Varicellovirus |
| Deposited As： | Equine Herpesvirus |
| Agent： | Equid herpesvirus 1 |
| Strain： | AB69 |
| Common Name： | Equine abortion virus |
| Applications： | vaccine production |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | infected lung tissue from an equine fetus aborted during a challenge study |
| Product Format： | frozen |
| Storage Conditions： | xa0 -70° or colder |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Comments： | -70C or lower |
| Effect on Host： | Yes, in vitro effects: Cytopathic effects (cell death with rounded foci of refractile cells and sloughing, typical herpesvirus CPE can be seen 1 to 2 days post-inoculation) CPE: cell death with rounded foci of refractile cells and sloughing, typical herpesvirus CPE can be seen 1-2 days post infection. |
| Growth Medium： | Minimum essential medium (Eagle) with 2 mM L-glutamine and Earles BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 95%; fetal bovine serum, 2%
|
| Recommended Host： | equine dermal cells (ATCC CCL-57) Host of Choice:xa0 E. dermal cells (ATCC CCL-57). Host Range: equine dermal cells, equine kidney cells, fetal xa0xa0xa0xa0xa0xa0xa0 xa0equine lung cells. E. Derm cells (ATCC CCL-57); equine kidney cells; fetal equine lung cells |
| Growth Conditions： | Temperature: 37.0°C Duration: 3-6 days at 37C, or until 95% CPE, in equine dermal cells (ATCC CCL-57) |
| Cryopreservation： | Storage temperature: -70C or lower |
| Name of Depositor： | Bayer Corp. Animal Health |
| U.S. Patent： | |
| U.S. Patent Number： | |
| Source： | infected lung tissue from an equine fetus aborted during a challenge study |
| References： | Macek J, et al. Cross-protective equine herpesvirus preparations and method of making and using the same. US Patent 5,853,715 dated Dec 29 1998 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Equid herpesvirus 1 |
|---|---|
| 商品货号： | TS213631 |
| Classification： | Herpesviridae, Varicellovirus |
| Deposited As： | Equine Herpesvirus |
| Agent： | Equid herpesvirus 1 |
| Strain： | AB69 |
| Common Name： | Equine abortion virus |
| Applications： | vaccine production |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation： | infected lung tissue from an equine fetus aborted during a challenge study |
| Product Format： | frozen |
| Storage Conditions： | xa0 -70° or colder |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Comments： | -70C or lower |
| Effect on Host： | Yes, in vitro effects: Cytopathic effects (cell death with rounded foci of refractile cells and sloughing, typical herpesvirus CPE can be seen 1 to 2 days post-inoculation) CPE: cell death with rounded foci of refractile cells and sloughing, typical herpesvirus CPE can be seen 1-2 days post infection. |
| Growth Medium： | Minimum essential medium (Eagle) with 2 mM L-glutamine and Earles BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 95%; fetal bovine serum, 2%
|
| Recommended Host： | equine dermal cells (ATCC CCL-57) Host of Choice:xa0 E. dermal cells (ATCC CCL-57). Host Range: equine dermal cells, equine kidney cells, fetal xa0xa0xa0xa0xa0xa0xa0 xa0equine lung cells. E. Derm cells (ATCC CCL-57); equine kidney cells; fetal equine lung cells |
| Growth Conditions： | Temperature: 37.0°C Duration: 3-6 days at 37C, or until 95% CPE, in equine dermal cells (ATCC CCL-57) |
| Cryopreservation： | Storage temperature: -70C or lower |
| Name of Depositor： | Bayer Corp. Animal Health |
| U.S. Patent： | |
| U.S. Patent Number： | |
| Source： | infected lung tissue from an equine fetus aborted during a challenge study |
| References： | Macek J, et al. Cross-protective equine herpesvirus preparations and method of making and using the same. US Patent 5,853,715 dated Dec 29 1998 |
